PURPOSE: The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. METHODS: PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks. RESULTS: Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic. CONCLUSION: PZA at the dose and schedule employed has insignificant activity in this population.
PURPOSE: The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. METHODS:PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks. RESULTS: Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic. CONCLUSION:PZA at the dose and schedule employed has insignificant activity in this population.
Authors: G A Omura; J A Blessing; L Vaccarello; M L Berman; D L Clarke-Pearson; D G Mutch; B Anderson Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: M M Zalupski; A F Shields; P A Philip; M Kraut; P LoRusso; L K Heilbrun; V Vaitkevicius Journal: Invest New Drugs Date: 1998 Impact factor: 3.850
Authors: P LoRusso; B J Foster; E Poplin; J McCormick; M Kraut; L Flaherty; L K Heilbrun; M Valdivieso; L Baker Journal: Clin Cancer Res Date: 1995-12 Impact factor: 12.531
Authors: Bhuvaneswari Ramaswamy; Ewa Mrozek; John Philip Kuebler; Tanios Bekaii-Saab; Eric H Kraut Journal: Invest New Drugs Date: 2009-10-21 Impact factor: 3.850
Authors: David Scott Miller; John A Blessing; Lois M Ramondetta; Huyen Q Pham; Krishnansu S Tewari; Lisa M Landrum; Jubilee Brown; Robert S Mannel Journal: J Clin Oncol Date: 2014-07-28 Impact factor: 44.544